Hodgkin lymphoma: Answers take time!

Blood

Volumn 117, Issue 20, 2011, Pages 5274-5276

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYTOPENIA; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79956369209     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-340307     Document Type: Article

References (10)

1. Straus DJ, Johnson JL, Lacasce AS, et al. Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117(20):5314-5320.
2. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
3. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108. (Pubitemid 34408801)
4. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):1989-1996. (Pubitemid 35001228)
5. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26(32):5170-5174.
6. Connors JM. Evolving approaches to primary treatment of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2005;239-244.
7. Advani RH, Hoppe RT, Maeda LS, et al. Stage I-IIA Non-bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience [published online ahead of print October 7, 2010]. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp. 2010.07.041.
8. Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003;98(5):978-982. (Pubitemid 37022098)
9. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10yearsoffollow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
10. Raemaekers JM. Actions following the interim analysis of the EORTC/GELA/IIL Intergroup H10 trial. Proceedings of Eighth International Symposium on Hodgkin lymphoma, Cologne, Germany 2010.